Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT
Autore:
Grunhaus, L; Hirschman, S; Dolberg, OT; Schreiber, S; Dannon, PN;
Indirizzi:
Chaim Sheba Med Ctr, Div Psychiat, IL-52621 Tel Hashomer, Israel Chaim Sheba Med Ctr Tel Hashomer Israel IL-52621 21 Tel Hashomer, Israel Shaar Menashe Psychiat Hosp, Hadera, Israel Shaar Menashe Psychiat Hosp Hadera Israel Psychiat Hosp, Hadera, Israel
Titolo Testata:
JOURNAL OF ECT
fascicolo: 2, volume: 17, anno: 2001,
pagine: 124 - 128
SICI:
1095-0680(200106)17:2<124:COMAFD>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
MAJOR DEPRESSIVE DISORDER; NATIONAL-COMORBIDITY-SURVEY; SEASONAL AFFECTIVE-DISORDER; ELECTROCONVULSIVE-THERAPY; PSYCHIATRIC-DISORDERS; SERUM MELATONIN; NOCTURNAL MELATONIN; ELECTRODE PLACEMENT; SLEEP DISTURBANCES; MEDICAL OUTCOMES;
Keywords:
manic depressive disorder; melatonin; major depression; electroconvulsive therapy; outcome;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Grunhaus, L Chaim Sheba Med Ctr, Div Psychiat, IL-52621 Tel Hashomer, Israel Chaim Sheba Med Ctr Tel Hashomer Israel IL-52621 mer, Israel
Citazione:
L. Grunhaus et al., "Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT", J ECT, 17(2), 2001, pp. 124-128

Abstract

At least 50% of patients with manic depressive disorder (MDD) treated successfully with electroconvulsive therapy (ECT) will experience a relapse within the first year of follow-up. Sleep disturbances are very common in MDD and may constitute forerunners of relapse. In this study we tested the hypothesis that melatonin, a sleep-promoting hormone, would decrease the 3-month relapse rate after successful ECT. We included in the study patients with MDD successfully treated with ECT (post-ECT Hamilton Rating Scale for Depression [HRSD] less than or equal to 10). Patients were blindly randomized to two groups, one receiving fluoxetine + placebo and one receiving fluoxetine + melatonin. Assessments (HRSD, Brief Psychiatric Rating Scale, Global Assessment of Function Scale, Global Depression Scale. Pittsburgh Sleep Quality Index, Mini-Mental State Exam. and pill count) were performed for 12 weeks after ECT. Ten of the 35 patients (28.5%) relapsed during the follow-up period. Relapse rates were similar in both groups of patients. Sleep reports were not improved by melatonin. Patients who achieved a higher functional state post-ECT relapsed less often. We conclude that the addition of melatonin to on-going fluoxetine treatment did not have a beneficial effect either on the 3-month outcome post-ECT or on the sleep reports of these patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 17:30:17